跳至主要内容
临床试验/ISRCTN48560305
ISRCTN48560305已完成未知

Are early and late cardiovascular risk markers in women with polycystic ovary syndrome increased with concomitant non-alcoholic steatohepatitis and can this be modified with liraglutide?

Hull and East Yorkshire Hospitals NHS Trust (UK)0 个研究点目标入组 40 人开始时间: 2012年5月22日最近更新:

试验速览

阶段
未知
状态
已完成
发起方
入组人数
40

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

性别
Female

入选标准

  • Polycystic ovary syndrome (defined by the Rotterdam criteria) as 2 out of 3 of:
  • 1. Oligo / anovulation
  • 2. Clinical or biochemical evidence of hirsuitism, and/or
  • 3. Polycystic ovaries on ultrasound and the exclusion of other disorders
  • 4. Age 18-45 years
  • For normal controls:
  • 1. Female, aged 18 - 45
  • 2. Body madd index (BMI) 30 - 45
  • 3. No current medical problems

排除标准

  • 1. Ketoacidosis
  • 2. Severe gastrointestinal disease
  • 3. Hypothyroidism
  • 4. Subjects taking regular medications associated with high risk of hepatotoxicity like isoniazid and methotrexate
  • 5. Not using a reliable method of contraception
  • 6. Patients not allowing disclosure to their GP's
  • 7. History of pancreatitis
  • 8. Heart Failure
  • 9. Chronic renal failure (creatinine clearance less than 60 ml/min or plasma creatinine >150 umol/L)
  • 10. Pregnancy or breastfeeding women
  • 11. Liver function tests >300% reference range normal (eg ALT>90 u/mL)
  • 12. Type 2 diabetes mellitus
  • 13. Acute conditions with the potential to alter renal function such as: dehydration / severe infection / shock / intravascular administration of iodinated contrast

研究者

发起方
Hull and East Yorkshire Hospitals NHS Trust (UK)

相似试验

进行中(未招募)
不适用
Are early and late cardiovascular risk markers in women with Polycystic Ovary Syndrome increased with concomitant Nonalcoholic Steatohepatitis and can this be modified with Exenatide? - CV risk in PCOS and NASH
EUCTR2008-006928-55-GBHull and East Yorkshire NHS Trust
进行中(未招募)
1 期
Are early and late cardiovascular risk markers in women with Polycystic Ovary Syndrome increased with concomitant Nonalcoholic Steatohepatitis and can this be modified with Liraglutide?Polycystic Ovary Syndrome Non-alcoholic SteatohepatitisMedDRA version: 12.0 Level: LLT Classification code 10065161 Term: Polycystic ovarian syndromeMedDRA version: 12.0 Level: LLT Classification code 10053219 Term: Non-alcoholic steatohepatitis
EUCTR2009-015927-94-GBHull and East Yorkshire NHS Trust
已完成
不适用
Are early and late cardiovascular risk markers in women with polycystic ovary syndrome (PCOS) increased with concomitant non-alcoholic steatohepatitis (NASH) and can this be modified with exenatide?Polycystic ovary syndrome, non-alcoholic steatohepatitisNutritional, Metabolic, EndocrineOvarian dysfunction
ISRCTN81902209Hull and East Yorkshire Hospitals NHS Trust (UK)20
已完成
不适用
Early detection of cardiovascular risk factors after pregnancy complicated by hypertensive disorders or spontaneous preterm birthcardiovascular disease after hypertensive disorders in pregnancy or after spontaneous preterm birth100192801002690810057166
NL-OMON45089Vrije Universiteit Medisch Centrum687
已完成
不适用
Biomarkers and cardiovascular risk in disease models of non-alcoholic fatty liver diseasefatty liver
NL-OMON48654Medisch Universitair Ziekenhuis Maastricht85